203 related articles for article (PubMed ID: 30517931)
1. Sickle Cell Nephropathy in the Pediatric Population.
Olaniran KO; Eneanya ND; Nigwekar SU; Vela-Parada XF; Achebe MM; Sharma A; Thadhani RI
Blood Purif; 2019; 47(1-3):205-213. PubMed ID: 30517931
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients.
Kaspar CDW; Beach I; Newlin J; Sisler I; Feig D; Smith W
Pediatr Nephrol; 2020 May; 35(5):883-889. PubMed ID: 31960140
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Laurin LP; Nachman PH; Desai PC; Ataga KI; Derebail VK
Nephrol Dial Transplant; 2014 Jun; 29(6):1211-8. PubMed ID: 24084325
[TBL] [Abstract][Full Text] [Related]
4. Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study.
Zahr RS; Yee ME; Weaver J; Twombley K; Matar RB; Aviles D; Sreedharan R; Rheault MN; Malatesta-Muncher R; Stone H; Srivastava T; Kapur G; Baddi P; Volovelsky O; Pelletier J; Gbadegesin R; Seeherunvong W; Patel HP; Greenbaum LA
Pediatr Nephrol; 2019 Aug; 34(8):1435-1445. PubMed ID: 30945006
[TBL] [Abstract][Full Text] [Related]
5. Sickle cell disease nephropathy: an update on risk factors and potential biomarkers in pediatric patients.
Belisário AR; da Silva AA; Silva CV; de Souza LM; Wakabayashi EA; Araújo SA; Simoes-E-Silva AC
Biomark Med; 2019 Aug; 13(11):967-987. PubMed ID: 31390894
[TBL] [Abstract][Full Text] [Related]
6. Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease.
Thrower A; Ciccone EJ; Maitra P; Derebail VK; Cai J; Ataga KI
Br J Haematol; 2019 Jan; 184(2):246-252. PubMed ID: 30460977
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system blockade promotes a cardio-renal protection in albuminuric homozygous sickle cell patients.
Haymann JP; Hammoudi N; Stankovic Stojanovic K; Galacteros F; Habibi A; Avellino V; Bartolucci P; Benzerara Y; Arlet JB; Djebbar M; Letavernier E; Grateau G; Tabibzadeh N; Girshovich A; Chaignon M; Girot R; Levy P; Lionnet F
Br J Haematol; 2017 Dec; 179(5):820-828. PubMed ID: 29048108
[TBL] [Abstract][Full Text] [Related]
8. Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia.
Yee ME; Lane PA; Archer DR; Joiner CH; Eckman JR; Guasch A
Blood Cells Mol Dis; 2018 Mar; 69():65-70. PubMed ID: 28951038
[TBL] [Abstract][Full Text] [Related]
9. Urinary Transforming Growth Factor β-1 as a Marker of Renal Dysfunction in Sickle Cell Disease.
Ghobrial EE; Abdel-Aziz HA; Kaddah AM; Mubarak NA
Pediatr Neonatol; 2016 Jun; 57(3):174-80. PubMed ID: 26508723
[TBL] [Abstract][Full Text] [Related]
10. Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease.
Bergmann S; Zheng D; Barredo J; Abboud MR; Jaffa AA
J Pediatr Hematol Oncol; 2006 Mar; 28(3):147-53. PubMed ID: 16679937
[TBL] [Abstract][Full Text] [Related]
11. Nephrotic syndrome on sickle cell disease: the impact of Hydroxyurea.
Cunha M; Simão C; Ferrão A; Palaré MJ
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33674289
[TBL] [Abstract][Full Text] [Related]
12. The nephropathy of sickle cell trait and sickle cell disease.
Ataga KI; Saraf SL; Derebail VK
Nat Rev Nephrol; 2022 Jun; 18(6):361-377. PubMed ID: 35190716
[TBL] [Abstract][Full Text] [Related]
13. Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease.
Tehseen S; Joiner CH; Lane PA; Yee ME
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612449
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease.
McKie KT; Hanevold CD; Hernandez C; Waller JL; Ortiz L; McKie KM
J Pediatr Hematol Oncol; 2007 Mar; 29(3):140-4. PubMed ID: 17356390
[TBL] [Abstract][Full Text] [Related]
16. Nephrin as a biomarker of sickle cell glomerulopathy in Malawi.
Heimlich JB; Chipoka G; Elsherif L; David E; Ellis G; Kamthunzi P; Krysiak R; Mafunga P; Zhou Q; Cai J; Gopal S; Key NS; Ataga KI
Pediatr Blood Cancer; 2018 Jun; 65(6):e26993. PubMed ID: 29411937
[TBL] [Abstract][Full Text] [Related]
17. Sickle Cell Disease and Kidney.
Amarapurkar P; Roberts L; Navarrete J; El Rassi F
Adv Chronic Kidney Dis; 2022 Mar; 29(2):141-148.e1. PubMed ID: 35817521
[TBL] [Abstract][Full Text] [Related]
18. The kidney in sickle hemoglobinopathies
.
Airy M; Eknoyan G
Clin Nephrol; 2017 Feb; 87 (2017)(2):55-68. PubMed ID: 27900941
[TBL] [Abstract][Full Text] [Related]
19. The glomerulopathy of sickle cell disease.
Ataga KI; Derebail VK; Archer DR
Am J Hematol; 2014 Sep; 89(9):907-14. PubMed ID: 24840607
[TBL] [Abstract][Full Text] [Related]
20. Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Quimby KR; Hambleton IR; Landis RC
Med Hypotheses; 2015 Oct; 85(4):424-32. PubMed ID: 26141635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
